logo
logo
IRTC stock ticker logo

iRhythm Technologies, Inc.

NASDAQ•IRTC
CEO: Mr. Quentin S. Blackford
セクター: Healthcare
業種: Medical - Devices
上場日: 2016-10-20
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
連絡先情報
699 8th Street, Suite 600, San Francisco, CA, 94103, United States
415-632-5700
www.irhythmtech.com
時価総額
$3.65B
PER (TTM)
-81.8
26.6
配当利回り
--
52週高値
$212.00
52週安値
$92.52
52週レンジ
17%
順位62Top 92.6%
1.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$208.89M+0.00%
直近4四半期の推移

EPS

$0.17+0.00%
直近4四半期の推移

フリーCF

$14.49M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Revenue Growth Strong Net revenue reached $747.1M USD, marking 26% increase driven by higher service volumes and Zio AT adoption.
Gross Profit Margin Expansion Gross profit reached $527.3M USD, showing 29% growth due to better pricing and volume mix.
Net Loss Significantly Reduced Net loss narrowed to $(44.6)M USD, reflecting a substantial 61% reduction compared to prior year.
IPR&D Expense Reverts Acquired IPR&D expense dropped 91% to $3.0M USD following 2024 BioIntelliSense license charge.

リスク要因

Medicare Reimbursement Risk Reimbursement highly regulated; failure to comply with remote test rules risks penalties and revenue loss.
Competitive Monitoring Market Remote monitoring market is highly competitive; competitors developing more effective devices could reduce opportunities.
Significant Debt Load Servicing $661.3M USD in 2029 Notes requires substantial cash flow, impacting future financial flexibility.
Ongoing Legal Proceedings Company faces ongoing patent litigation risks; adverse outcomes could result in damages or prohibit product use.

見通し

Expand Core Monitoring Market Strategy focuses on penetrating core market, expanding utilization across cardiology and primary care specialties.
Adjacent Clinical Opportunities Pursuing proactive monitoring in adjacent areas like Sleep Apnea and Heart Failure using existing platform capabilities.
Advance Product Portfolio Investing in next-gen MCT device, 510(k) submitted Q3 2025, enhancing detection algorithms and insights.
International Expansion Focus Selectively expanding internationally in geographies with established regulatory pathways and reimbursement progression.

同業比較

売上高 (TTM)

OSCR stock ticker logoOSCR
$11.70B
+27.5%
BLCO stock ticker logoBLCO
$5.10B
+6.5%
BRKR stock ticker logoBRKR
$3.44B
+2.1%

粗利益率 (最新四半期)

ARWR stock ticker logoARWR
100.0%
+50.6pp
AXSM stock ticker logoAXSM
93.7%
+1.1pp
GKOS stock ticker logoGKOS
83.8%
+1.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
AXSM$7.98B-43.1-254.1%35.0%
PCVX$7.86B-9.7-25.9%7.5%
ARWR$7.71B38.136.1%19.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
9.6%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年4月29日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし